Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leflunomide in polymyalgia rheumatica
NL-OMON46948Phase 3Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing Leflunomide + prednisolone taper with Placebo + prednisolone taper (2 arms). Primary endpoint: Time to first relapse within 12 months. Started Mar 2019; status: recruiting.
02
Drugs
leflunomide
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON46948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46948.